Boehringer
Boehringer and Sanofi admit to code breaches
February 13, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, PMCPA, Sanofi, afatinib, giotrif
Sanofi and Boehringer Ingelheim have both admitted to breaching the ABPI Code of Practice, with Sanofi set to be publicly …
Boehringer and Lilly score FDA yes for Glyxambi
February 3, 2015Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin
The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …
Boehringer gains EU approval for Ofev
January 19, 2015Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev
The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …
Boehringer complaint ruled out by PMCPA
January 15, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, COPD, PMCPA, Striverdi, olodaterol
A complaint made by a pharmacist stating that the artwork image for Boehringer Ingelheim’s COPD drug Striverdi is misleading has …
Sanofi and Boehringer partner on biologics manufacturing
January 15, 2015Manufacturing and Production, Sales and Marketing Boehringer, Sanofi, antibodies, biologics, cardiovascular, diabetes, mabs, manufacturing, monoclonal, oncology
Boehringer Ingelheim will help Sanofi extend its manufacturing capabilities for biologics in a new alliance, the companies have announced. Boehringer’s …
Boehringer gets NICE nod for Pradaxa
December 16, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin
NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …
Boehringer trials Pradaxa anti-bleeding antidote
December 11, 2014Sales and Marketing BMS, Bayer, Boehringer, Eliquis, Pradaxa, ash, dabigatran, idarucizumab
Boehringer Ingelheim says that its investigational drug can safely reverse the blood-thinning effect of its anti-clotting drug Pradaxa (dabigatran). The …
Boehringer’s lung cancer drug Vargatef sees EU approval
November 28, 2014Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef
Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …
CHMP nods several drugs through
November 24, 2014Sales and Marketing Boehringer, CHMP, EMA, Esbriet, FDA, Sanofi, nintedanib, ofev
Ten new medicines have been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP), among …
Reprieve for Boehringer plant as Chinese buyer comes forward
November 3, 2014Manufacturing and Production Boehringer, China, Petersburg, UniTao Pharmaceuticals
A US manufacturing facility cued up for closure by Boehringer Ingelheim has been bought by a Chinese drugmaker. Boehringer had …
NICE recommends new indication for troubled Pradaxa
October 31, 2014Sales and Marketing Boehringer, NHS, NICE, Pradaxa, dabigatran, ingelheim, warfarin
NICE has recommended Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa for treating and preventing potentially-fatal blood clots in the legs …
Boehringer seeks more indications for IPF drug
October 22, 2014Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev
Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …
Boehringer and Roche IPF drugs win FDA approval
October 16, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev
The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …
Gamification: what’s in it for the pharma industry?
October 6, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AF, Boehringer, COPD, CRUK, Gamification, ROI, Syrum, digital
Gamification is the new buzzword in digital marketing and has the potential to engage consumers more than traditional strategies. This …
Boehringer spends €100 million on inhaler
September 30, 2014Manufacturing and Production, Sales and Marketing Boehringer, Germany, Spiriva, Striverdi, inhaler, olodaterol, respimat
Boehringer Ingelheim is to spend more than €100 million at its Dortmund site in Germany in order to expand the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
